KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non-Current Debt: 2017-2021

Historic Non-Current Debt for Alnylam Pharmaceuticals (ALNY) over the last 4 years, with Dec 2021 value amounting to $675.7 million.

  • Alnylam Pharmaceuticals' Non-Current Debt rose 253.25% to $675.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was $675.7 million, marking a year-over-year increase of 253.25%. This contributed to the annual value of $675.7 million for FY2021, which is 253.25% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Non-Current Debt of $675.7 million as of FY2021, which was up 253.25% from $191.3 million recorded in FY2020.
  • Alnylam Pharmaceuticals' 5-year Non-Current Debt high stood at $675.7 million for FY2021, and its period low was $30.0 million during FY2017.
  • Over the past 2 years, Alnylam Pharmaceuticals' median Non-Current Debt value was $433.5 million (recorded in 2020), while the average stood at $433.5 million.
  • Data for Alnylam Pharmaceuticals' Non-Current Debt shows a peak YoY spiked of 253.25% (in 2021) over the last 5 years.
  • Yearly analysis of 4 years shows Alnylam Pharmaceuticals' Non-Current Debt stood at $30.0 million in 2017, then remained steady at $30.0 million in 2018, then reached $191.3 million in 2020, then soared by 253.25% to $675.7 million in 2021.